Published online before print April 7, 2003, doi: 10.1161/01.CIR.0000066852.98038.D1
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:1840.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty
From Internal Medicine II, University of Ulm, Ulm, Germany.
Correspondence to PD Dr Martin Höher, FESC, Internal-Medicine-II, University of Ulm, Robert-Koch-Strasse-8, 89081 Ulm, Germany. E-mail martin.hoeher{at}medizin.uni-ulm.de
Background— In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Clinical trials have studied intravenous administration only. Intracoronary bolus application of abciximab causes very high local drug concentrations and may be more effective. We studied whether intracoronary bolus administration of abciximab is associated with a reduced MACE rate compared with the standard intravenous bolus application.
Methods and Results— We stratified 403 consecutive patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty according to the type of application of abciximab. A 20-mg bolus of abciximab was given intravenously in 109 patients and intracoronarily in 294 patients. There were no differences between the groups with regard to diabetes mellitus, cardiogenic shock, successful intervention, or preprocedural and postprocedural TIMI flow. At 30 days, the incidence of MACE (death, myocardial infarction, urgent revascularization) was significantly lower in the patients with intracoronary compared with intravenous administration of abciximab (10.2% versus 20.2%; P<0.008), which was independent from stenting in multivariate analysis. The effect was most pronounced in patients with preprocedural TIMI 0/1 flow (MACE: intracoronary 11.8% versus intravenous 27.5%, P<0.002; n=273).
Conclusions— In patients with acute myocardial infarction or unstable angina undergoing emergency coronary angioplasty, intracoronary bolus application of abciximab is associated with a reduction of MACE compared with the standard intravenous bolus application of abciximab. Prospective, randomized trials are warranted to further assess intracoronary application of abciximab.
Key Words: angioplasty • stents • glycoproteins • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  R. H. Mehta, F.-S. Ou, E. D. Peterson, R. E. Shaw, W. B. Hillegass Jr, J. S. Rumsfeld, M. T. Roe, and American College of Cardiology-National Cardiovasc Clinical Significance of Post-Procedural TIMI Flow in Patients With Cardiogenic Shock Undergoing Primary Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 56 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Coller and S. J. Shattil The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend Blood, October 15, 2008; 112(8): 3011 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Gibson, C. Zorkun, and V. Kunadian Intracoronary Administration of Abciximab in ST-Elevation Myocardial Infarction Circulation, July 1, 2008; 118(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
|
|
H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz, et al. Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial Circulation, July 1, 2008; 118(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Patel, H. Rana, and D. A. N. Mascarenhas Intracoronary Abciximab Use in Patients Undergoing PCI at a Community Hospital: A Single Operator Experience Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2008; 13(2): 89 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Merkle, J. Wohrle, O. Grebe, T. Nusser, M. Kunze, H. A Kestler, M. Kochs, and V. Hombach Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state, free-precession magnetic resonance first-pass imaging Heart, November 1, 2007; 93(11): 1381 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Carey and J. C. Blankenship A Sequential Approach to the Management of a Massive Intracoronary Thrombus in ST Elevation Myocardial Infarction: A Case Report Angiology, February 1, 2007; 58(1): 106 - 111. [Abstract] [PDF]
|
|
|
|
|
|
S. Sharma, R. Makkar, and J. Lardizabal Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 136 - 141. [Abstract] [PDF]
|
|
|
|
|
|
N. Marx, J. Wohrle, T. Nusser, D. Walcher, A. Rinker, V. Hombach, W. Koenig, and M. Hoher Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation: A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients Circulation, November 1, 2005; 112(18): 2792 - 2798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. De Luca, H. Suryapranata, G. W. Stone, D. Antoniucci, J. E. Tcheng, F.-J. Neumann, F. Van de Werf, E. M. Antman, and E. J. Topol Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-analysis of Randomized Trials JAMA, April 13, 2005; 293(14): 1759 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hombach, O. Grebe, N. Merkle, S. Waldenmaier, M. Hoher, M. Kochs, J. Wohrle, and H. A. Kestler Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging Eur. Heart J., March 2, 2005; 26(6): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Horton Glycoprotein IIb/IIIa Inhibition JAMA, November 10, 2004; 292(18): 2211 - 2211. [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot, M. Borentain, L. Payot, J. P. Collet, and D. Thomas Glycoprotein IIb/IIIa Inhibition--Reply JAMA, November 10, 2004; 292(18): 2211 - 2212. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steiner-Boker, M. Cejna, C. Nasel, E. Minar, and C. W. Kopp Successful Revascularization of Acute Carotid Stent Thrombosis by Facilitated Thrombolysis AJNR Am. J. Neuroradiol., September 1, 2004; 25(8): 1411 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Simon and M. Sakuma Platelet disaggregation: Putting time on your side in acute myocardial infarction J. Am. Coll. Cardiol., July 21, 2004; 44(2): 324 - 326. [Full Text] [PDF]
|
|
|
|
|
|
F. Burzotta, E. Romagnoli, C. Trani, F. Crea, J. Wohrle, O. C. Grebe, T. Nusser, E. Al-Khayer, S. Schaible, M. Kochs, et al. Intracoronary Administration of Abciximab Acutely Increases Flow Through Culprit Vessels of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention * Response Circulation, November 11, 2003; 108 (19): e138 - e138. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steiner, D. Seidinger, K. Huber, C. Kaun, E. Minar, and C. W. Kopp Effect of Glycoprotein IIb/IIIa Antagonist Abciximab on Monocyte-Platelet Aggregates and Tissue Factor Expression Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Intracoronary Abciximab Limits MACE During Emergent PCI Journal Watch Cardiology, May 23, 2003; 2003(523): 1 - 1. [Full Text]
|
|